| Autor: |
Majowicz A; uniQure N.V., Amsterdam, the Netherlands., Nijmeijer B; uniQure N.V., Amsterdam, the Netherlands., Lampen MH; uniQure N.V., Amsterdam, the Netherlands., Spronck L; uniQure N.V., Amsterdam, the Netherlands., de Haan M; uniQure N.V., Amsterdam, the Netherlands., Petry H; uniQure N.V., Amsterdam, the Netherlands., van Deventer SJ; uniQure N.V., Amsterdam, the Netherlands., Meyer C; uniQure N.V., Amsterdam, the Netherlands., Tangelder M; uniQure N.V., Amsterdam, the Netherlands., Ferreira V; uniQure N.V., Amsterdam, the Netherlands. |
| Abstrakt: |
Currently, individuals with pre-existing neutralizing antibodies (NABs) against adeno-associated virus (AAV) above titer of 5 are excluded from systemic AAV-based clinical trials. In this study we explored the impact of pre-existing anti-AAV5 NABs on the efficacy of AAV5-based gene therapy. AMT-060 (AAV5-human FIX) was evaluated in 10 adults with hemophilia B who tested negative for pre-existing anti-AAV5 NABs using a GFP-based assay. In this study, using a more sensitive luciferase-based assay, we show that 3 of those 10 patients tested positive for anti-AAV5 NABs. However, no relationship was observed between the presence of pre-treatment anti-AAV5 NABs and the therapeutic efficacy of AMT-060. Further studies in non-human primates (NHPs) showed that AAV5 transduction efficacy was similar following AMT-060 treatment, irrespective of the pre-existing anti-AAV5 NABs titers. We show that therapeutic efficacy of AAV5-mediated gene therapy was achieved in humans with pre-existing anti-AAV5 NABs titers up to 340. Whereas in NHPs circulating human factor IX (hFIX) protein was achieved, at a level therapeutic in humans, with pre-existing anti-AAV5 NABs up to 1030. Based on those results, no patients were excluded from the AMT-061 (AAV5-hFIX-Padua) phase IIb clinical trial (n = 3). All three subjects presented pre-existing anti-AAV5 NABs, yet had therapeutic hFIX activity after AMT-061 administration. |
